Alkermes plc (NASDAQ:ALKS)’s traded shares stood at 2.21 million during the latest session, with the company’s beta value hitting 0.46. At the last check today, the stock’s price was $27.45, to imply a decrease of -1.44% or -$0.4 in intraday trading. The ALKS share’s 52-week high remains $32.88, putting it -19.78% down since that peak but still an impressive 25.46% since price per share fell to its 52-week low of $20.46. The company has a valuation of $4.52B, with an average of 1.48 million shares in intraday trading volume over the past 10 days and average of 1.69 million shares over the past 3 months.

Analysts have given a consensus recommendation of Buy for Alkermes plc (ALKS), translating to a mean rating of 2.07. Of 8 analyst(s) looking at the stock, 0 analyst(s) give ALKS a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 6 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.74.

Alkermes plc (NASDAQ:ALKS) trade information

After registering a -1.44% downside in the latest session, Alkermes plc (ALKS) has traded red over the past five days. The 5-day price performance for the stock is -3.11%, and 3.86% over 30 days. With these gigs, the year-to-date price performance is -1.05%. Short interest in Alkermes plc (NASDAQ:ALKS) saw shorts transact 17.18 million shares and set a 9.83 days time to cover.

The extremes give us $27 and $50 for target low and target high price respectively. As such, ALKS has been trading -82.15% off suggested target high and 1.64% from its likely low.

Alkermes plc (ALKS) estimates and forecasts

Looking at statistics comparing Alkermes plc share performance against respective industry, we note that the company has underperformed competitors. Alkermes plc (ALKS) shares are 12.32% up over the last 6 months, with its year-to-date growth rate lower than industry average at 14.96% against 17.50%. Revenue is forecast to grow 15.60% this quarter before jumping 263.60% for the next one. The rating firms project that company’s revenue will shrink -9.40% compared to the previous financial year.

Revenue forecast for the current quarter as set by 13 analysts is 380.64M. Meanwhile, for the current quarter, a total of 13 analyst(s) estimate revenue growth to 376.62M.Earnings reports from the last fiscal year show that sales brought in 362.15M and 377.48M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 5.10% before dropping -0.20% in the following quarter.

ALKS Dividends

Alkermes plc has its next earnings report out on 2024-Oct-24. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Alkermes plc (NASDAQ:ALKS)’s Major holders

Alkermes plc insiders hold 1.31% of total outstanding shares, with institutional holders owning 112.26% of the shares at 113.75% float percentage. In total, 112.26% institutions holds shares in the company, led by BLACKROCK INC. As of 2024-06-30, the company held over 29.11 million shares (or 17.3276% of shares), all amounting to roughly $701.49 million.

The next major institution holding the largest number of shares is VANGUARD GROUP INC with 20.0 million shares, or about 11.9058% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $482.0 million.

We also have iShares Core S&P Smallcap ETF and Vanguard Specialized-Health Care Fund as the top two Mutual Funds with the largest holdings of the Alkermes plc (ALKS) shares. Going by data provided on Sep 30, 2024, iShares Core S&P Smallcap ETF holds roughly 10.46 shares. This is just over 6.35% of the total shares, with a market valuation of $289.78 million. Data from the same date shows that the other fund manager holds a little less at 8.6, or 5.22% of the shares, all valued at about 238.4 million.